Tag Archive for: PSMA
Phase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/in Clinical Trial, Metastatic, Phase 1/by MaxCTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”
/in Preclinical Research/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026